MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
0.3502
-0.0050
-1.41%
Pre Market: 0.3595 +0.0093 +2.66% 05:06 05/09 EDT
OPEN
0.3553
PREV CLOSE
0.3552
HIGH
0.3564
LOW
0.2742
VOLUME
750
TURNOVER
123.19K
52 WEEK HIGH
66.33
52 WEEK LOW
0.2196
MARKET CAP
8.17M
P/E (TTM)
-0.0074
1D
5D
1M
3M
1Y
5Y
1D
Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial
TipRanks · 20h ago
TransCode Therapeutics Faces Nasdaq Delisting Risk
TipRanks · 1d ago
TransCode Therapeutics Announces Reverse Stock Split
TipRanks · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at RNAZ last week (0428-0502)?
Weekly Report · 3d ago
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert
Benzinga · 3d ago
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday
Benzinga · 4d ago
More
About RNAZ
More
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
Recently
Symbol
Price
%Change

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.